Transocean Ltd vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Transocean Ltd trades at $5.57 (market cap $6.02B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.24 (market cap $2.28B). The key difference: Transocean Ltd is far larger — about 2.6× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Transocean Ltd nearer its low. Which is the better fit depends on your goals.
| RIG | SLS | |
|---|---|---|
Market Cap | $6.02B | $2.28B |
Volume | 19,180,005 | 3,128,960 |
Sector | Energy | Health |
52-Week High | $7.58 | $15.46 |
52-Week Low | $3.08 | $1.39 |
Typical Hold Time | 18 Days | — |
Enterprise Value | $10.63B | $2.15B |
Signals from Pluang's Aura AI — not financial advice
RIG trades at $5.39, down 0.19% on the day, with a mixed technical picture showing bearish moving averages but neutral oscillators. The company reported a net loss of $2.92 billion in 2025, though revenue remains solid at $3.97 billion. Recent news highlights progress on the $5.8 billion Valaris acquisition and new contract wins, while analyst sentiment is divided with a 39% buy rating.
The outlook hinges on successful deleveraging and offshore cycle strength, but high debt and persistent losses pose significant risks. Investment appeal is speculative, dependent on cash flow improvements and debt reduction outweighing current profitability challenges.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →